Sugi Predict

Sugi Predict / Compounds / SCHEMBL154245

SCHEMBL154245

SCHEMBL154245

O=C(O)c1sc(Br)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 3/20 0.44
▸ GSK3B P49841 1/20 0.42
▸ DAO P14920 5/20 0.42
▸ MCL1 Q07820 4/20 0.38
▸ BCKDK O14874 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ BCL2L1 Q07817 1/20 0.36
▸ TTR P02766 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13277701 0.81 GSK3B (0.41) GPR35GSK3BDAORXFP1ALDH1A1
SCHEMBL23997366 0.81 GSK3B (0.44) GSK3BDAOMAPK1RXFP1TSHR
SCHEMBL788357 0.77 DAO (0.50) GPR35GSK3BDAOMCL1BCKDK
SCHEMBL15878596 0.77 GSK3B (0.61) GPR35GSK3BDAORXFP1TTR
SCHEMBL26962809 0.76 MAPT (0.42) GSK3BMAPK1TSHRALDH1A1HPGD
SCHEMBL1974281 0.76 GSK3B (0.44) GPR35GSK3BDAORXFP1TSHR
SCHEMBL18701713 0.76 DAO (0.65) GPR35GSK3BDAOMCL1BCKDK
SCHEMBL31223143 0.76 GSK3B (0.44) GPR35GSK3BDAOMAPK1RXFP1
SCHEMBL20439913 0.74 DAO (0.42) GPR35DAOMCL1BCKDKMAPK1
SCHEMBL20894252 0.74 GSK3B (0.42) GPR35GSK3BDAOBCKDKRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
EP-4676476-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION Aquinnah Pharmaceuticals, Inc. (US) 2026-01-14 — — EP disclosed
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
CN-115836054-B IL4I1 inhibitors and methods of use 默沙东有限责任公司 2024-12-10 — — CN disclosed
WO-2024187126-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION AQUINNAH PHARMACEUTICALS, INC. (US) 2024-09-12 — — WO disclosed
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2024-05-02 — — US disclosed
EP-4291551-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2023-12-20 — — EP disclosed
CN-116888101-A Substituted isoxazoline derivatives 巴斯夫欧洲公司 2023-10-13 — — CN disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 — — US disclosed
US-20120258913-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-10-11 — — US disclosed
US-8222219-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-17 — — US disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
CN-1829729-A Novel compounds TANABE SEIYAKU CO (JP) 2006-09-06 — — CN disclosed
EP-1651658-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2006-05-03 — — EP disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 — — US disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR35 3074/4885GSK3B 706/4885DAO 860/4885
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 GPR35 2580/4885GSK3B 1789/4885DAO 586/4885
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 GPR35 2402/4885GSK3B 1258/4885DAO 599/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR35 3074/4885GSK3B 706/4885DAO 860/4885
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 GPR35 3843/4885GSK3B 2766/4885DAO 3751/4885
US-20120258913-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR35 3074/4885GSK3B 706/4885DAO 860/4885
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES CYP4X1, PRDX5, PRDX1 GPR35 2246/4885GSK3B 239/4885DAO 223/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 GPR35 3843/4885GSK3B 2766/4885DAO 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.